Session 6 – Protein Drugs and Combination Products
Date: 25 July (Thursday) 14:00 – 17:30 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom B
Judy H. Chou
SVP & Global Head of Biotech
With more than 20 years of experience in biomanufacturing and drug development, Dr. Judy Chou currently heads the global Biotech organization with 2000+ employees with the responsibilities of overseeing the manufacturing and distribution of Bayer’s $3+ billion/year biotechnology product portfolio and leading the drug development activities for biologics pipeline. In addition, she serves as the site head for Bayer’s facility in Berkeley, CA, USA. She is well recognized by the biomedical industry, and has received the Most Influential Women in Business Award in 2018.
Before Bayer, she held the role of Vice President of Pharmaceutical /Technical Operations at Pfizer, Inc., formerly Medivation, where she led the Development and Manufacturing organizations for both biologics and small molecule products. She was also Vice President of R&D at Tanvex Biopharma, Inc., where Dr. Chou successfully enabled the company’s IPO. Throughout Dr. Chou’s career, she has achieved significant milestones in protein therapeutic development and multiple filings of BLAs and INDs of novel products and is recognized for her work at Genentech, Wyeth, and Abbott especially in the development of breakthrough technologies in analytical characterization and the accelerated process and formulation development.
Before joining the industry, Dr. Chou was a research faculty member at Harvard University Medical School, focused on cell biology and neuroscience research. Dr. Chou obtained her Ph.D. from Yale University and completed her post-doctoral training at Max-Planck Institute in Germany Session Speech Title & Synopsis: Protein Therapeutics and Combination Products Today and Tomorrow
Recently approved recombinant protein therapeutics have been expanded to treat a wide variety of clinical indications with additional mechanisms of actions. The latest advances in protein-engineering technologies have allowed drug developers and manufacturers to fine-tune and exploit desirable functional characteristics of proteins of interest while maintaining product safety or efficacy or both. With the combination of other therapeutic products and/or devices, the spectrum of protein therapeutics has been further broadened in pharmacological intervention by using several drugs that interact with multiple targets in the molecular networks of diseases, and in therapeutic effects by deploying technologies that enable and/or enhance the drug delivery pathways. The perspectives of current and future protein therapeutics and combination products will be presented.